![Sten Randahl Sörensen](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Sten Randahl Sörensen
Amministratore Delegato presso CERENO SCIENTIFIC AB
Profilo
Sten Randahl Sörensen is currently the Chief Executive Officer & Director at Cereno Scientific AB, the Executive Chairman at SARomics Biostructures AB, and the Director at SynAct Pharma AB.
Previously, he served as the Chairman at AcuCort AB and Stayble Therapeutics AB.
He also worked as the Director-Secondary Prevention Products Marketing at AstraZeneca AB.
From 1987 to 1995, he was the Head-International Marketing Operations at Monsanto Crop Sciences Sweden AB.
Mr. Sörensen completed his undergraduate degree at the University of Lund.
Posizioni attive di Sten Randahl Sörensen
Società | Posizione | Inizio |
---|---|---|
CERENO SCIENTIFIC AB | Amministratore Delegato | 01/09/2015 |
SYNACT PHARMA AB | Direttore/Membro del Consiglio | 20/03/2024 |
SARomics Biostructures AB
![]() SARomics Biostructures AB BiotechnologyHealth Technology SARomics Biostructures AB provides protein three-dimensional structure determination and structure-based drug discovery services. The firm develops premium structural biology services. It offers crystallography services, which include crystallization screen and structure determination, nuclear magnetic resonance spectroscopy services, such as ligand binding assays/fragment screening, structure determination, and verification of the structural integrity of target protein, gene-to-structure services, such as protein cloning, expression, purification, and structure determination, kinase structures and kinobits, which include pre-made complexes of kinases with small-molecule fragments to serve as a starting point in a discovery project, structure-based drug discovery services, such as hit identification, hit optimization, and lead generation, gene-to lead services, including a combination of gene-to-structure and structure-based drug discovery, and structure-activity protein optimization services. The company was founded by Björn Ulrik Walse, Sven Anders Mikael Akke, Derek W. Logan, Salam Al-Karadaghi, and Bo Svensson in 2006 and is headquartered in Lund, Sweden. | Presidente | 01/01/2013 |
Precedenti posizioni note di Sten Randahl Sörensen
Società | Posizione | Fine |
---|---|---|
Monsanto Crop Sciences Sweden AB | Vendite & Marketing | 01/01/1995 |
AstraZeneca AB
![]() AstraZeneca AB Miscellaneous Commercial ServicesCommercial Services AstraZeneca AB engages in biopharmaceutical business. It provides treatment of diseases in cardiovascular and metabolic diseases, cancer, respiratory, inflammation, and autoimmunity. The firm offers operations in the areas of infection, neuroscience, and stomach and intestinal diseases. The company was founded in 1999 and is headquartered in Sodertalje, Sweden. | Vendite & Marketing | - |
STAYBLE THERAPEUTICS AB | Presidente | - |
ACUCORT AB | Presidente | - |
Formazione di Sten Randahl Sörensen
University of Lund | Undergraduate Degree |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
Società quotate in Borsa | 4 |
---|---|
CERENO SCIENTIFIC AB | Health Technology |
ACUCORT AB | Health Technology |
STAYBLE THERAPEUTICS AB | Health Technology |
SYNACT PHARMA AB | Health Technology |
Aziende private | 3 |
---|---|
SARomics Biostructures AB
![]() SARomics Biostructures AB BiotechnologyHealth Technology SARomics Biostructures AB provides protein three-dimensional structure determination and structure-based drug discovery services. The firm develops premium structural biology services. It offers crystallography services, which include crystallization screen and structure determination, nuclear magnetic resonance spectroscopy services, such as ligand binding assays/fragment screening, structure determination, and verification of the structural integrity of target protein, gene-to-structure services, such as protein cloning, expression, purification, and structure determination, kinase structures and kinobits, which include pre-made complexes of kinases with small-molecule fragments to serve as a starting point in a discovery project, structure-based drug discovery services, such as hit identification, hit optimization, and lead generation, gene-to lead services, including a combination of gene-to-structure and structure-based drug discovery, and structure-activity protein optimization services. The company was founded by Björn Ulrik Walse, Sven Anders Mikael Akke, Derek W. Logan, Salam Al-Karadaghi, and Bo Svensson in 2006 and is headquartered in Lund, Sweden. | Health Technology |
Monsanto Crop Sciences Sweden AB | |
AstraZeneca AB
![]() AstraZeneca AB Miscellaneous Commercial ServicesCommercial Services AstraZeneca AB engages in biopharmaceutical business. It provides treatment of diseases in cardiovascular and metabolic diseases, cancer, respiratory, inflammation, and autoimmunity. The firm offers operations in the areas of infection, neuroscience, and stomach and intestinal diseases. The company was founded in 1999 and is headquartered in Sodertalje, Sweden. | Commercial Services |
- Borsa valori
- Insiders
- Sten Randahl Sörensen